The UCLA Prostate Cancer SPORE is a multidisciplinary and translational research program focused on the development of new and innovative approaches for improving the diagnosis, prognosis, and treatment of prostate cancer patients. The program?s reach includes collaborating investigators at local institutions such as Cedars Sinai and City of Hope in order to accelerate the goal of combating prostate cancer. A particular strength of the UCLA Prostate Cancer SPORE has been its ability to leverage institutional and NCI support to attract new human capital, technology, and ideas to the field of prostate cancer. Examples of these discoveries include: (1) the development of both the androgen receptor (AR) super-antagonists enzalutamide and apalutamide, (2) the discovery of the putative human prostate cancer stem cell of origin and its association with emergence of the lethal neuroendocrine phenotype, (3) the translation of novel engineered antibodies targeting Prostate Stem Cell Antigen (PSCA) to the clinic to target, treat and image prostate (and pancreatic) cancer, (4) the elucidation of signaling cross-talk between the PTEN/PI3K, AR, and ras/MAPK pathways in castrate resistant and treatment resistant prostate cancer (CRPC), and (5) the demonstration that a low fat diet supplemented with omega-3 fatty acids has measurable effects on prostate cancer and its mechanism of action. The overall goal of this competitive renewal application is to continue to apply the diversity of talent on the UCLA campus, its sister institutions and other institutions in Southern California to the critical and evolving translational challenges in the field of prostate cancer. To achieve the long-term objectives and goals of our program, the Specific Aims of the UCLA SPORE in Prostate Cancer are: (1) to perform high-impact translational research focused on some of the major challenges in the field of prostate cancer such as cancer metastasis, castration resistance, and treatment resistance, (2) to provide organizational infrastructure and novel technologies designed specifically to support the translational research objectives of the SPORE such as administrative, fiscal, and statistical support, and (3) to develop new prostate cancer researchers and research areas to advance translational research in prostate cancer through supporting innovative research in critical areas, pilot developmental research, and career development in prostate cancer research. Through these aims, UCLA Prostate Cancer SPORE can continue to promote significant and novel discoveries with potential major impact on men with prostate cancer.

Public Health Relevance

Prostate cancer is a major cause of morbidity and mortality in the US. The goal of our Prostate Cancer SPORE is to apply basic laboratory research to the goal of preventing, managing and curing all forms and stages of this disease. This will be accomplished through 4 major projects focused on critical unmet needs in this disease, pilot and developmental research programs, and core infrastructure support of research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA092131-16A1
Application #
9792320
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Arnold, Julia T
Project Start
2002-09-15
Project End
2024-08-31
Budget Start
2019-09-01
Budget End
2020-08-31
Support Year
16
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Urology
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Vidal, Adriana C; Howard, Lauren E; de Hoedt, Amanda et al. (2018) Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database. Cancer Causes Control 29:581-588
Vidal, Adriana C; Howard, Lauren E; de Hoedt, Amanda et al. (2018) Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int 122:76-82
Jelinek, David; Flores, Aimee; Uebelhoer, Melanie et al. (2018) Mapping Metabolism: Monitoring Lactate Dehydrogenase Activity Directly in Tissue. J Vis Exp :
Lee, John K; Bangayan, Nathanael J; Chai, Timothy et al. (2018) Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer. Proc Natl Acad Sci U S A 115:E4473-E4482
Mitra, Mithun; Lee, Ha Neul; Coller, Hilary A (2018) Determining Genome-wide Transcript Decay Rates in Proliferating and Quiescent Human Fibroblasts. J Vis Exp :
Zou, Yongkang; Qi, Zhi; Guo, Weilong et al. (2018) Cotargeting the Cell-Intrinsic and Microenvironment Pathways of Prostate Cancer by PI3K?/?/? Inhibitor BAY1082439. Mol Cancer Ther 17:2091-2099
Henning, Susanne M; Galet, Colette; Gollapudi, Kiran et al. (2018) Phase II prospective randomized trial of weight loss prior to radical prostatectomy. Prostate Cancer Prostatic Dis 21:212-220
Miller, Eric T; Salmasi, Amirali; Reiter, Robert E (2018) Anatomic and Molecular Imaging in Prostate Cancer. Cold Spring Harb Perspect Med 8:
Navarro, Héctor I; Goldstein, Andrew S (2018) HoxB13 mediates AR-V7 activity in prostate cancer. Proc Natl Acad Sci U S A 115:6528-6529
Mitra, Mithun; Ho, Linda D; Coller, Hilary A (2018) An In Vitro Model of Cellular Quiescence in Primary Human Dermal Fibroblasts. Methods Mol Biol 1686:27-47

Showing the most recent 10 out of 339 publications